TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Published:2015-03-16 Issue:12 Volume:21 Page:2722-2729
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Forero-Torres Andres,Varley Katherine E.,Abramson Vandana G.,Li Yufeng,Vaklavas Christos,Lin Nancy U.,Liu Minetta C.,Rugo Hope S.,Nanda Rita,Storniolo Anna M.,Traina Tiffany A.,Patil Sujata,Van Poznak Catherine H.,Nangia Julie R.,Irvin William J.,Krontiras Helen,De Los Santos Jennifer F.,Haluska Paul,Grizzle William,Myers Richard M.,Wolff Antonio C.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers;2024-07-23

2. Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics;eBioMedicine;2024-07

3. Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy;Biomacromolecules;2024-02-21

4. Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review;The Breast Journal;2024-01

5. Current and future prospective of caspases targeting in cancer therapy;Caspases as Molecular Targets for Cancer Therapy;2024